<bill session="116" type="h" number="7661" updated="2020-08-12T17:30:16Z">
  <state datetime="2020-07-16">REFERRED</state>
  <status>
    <introduced datetime="2020-07-16"/>
  </status>
  <introduced datetime="2020-07-16"/>
  <titles>
    <title type="short" as="introduced">Coronavirus EGC Extension Act</title>
    <title type="short" as="introduced">Coronavirus EGC Extension Act</title>
    <title type="display">Coronavirus EGC Extension Act</title>
    <title type="official" as="introduced">To temporarily prevent emerging growth companies from losing their status during the COVID-19 pandemic, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S001213"/>
  <cosponsors>
    <cosponsor bioguide_id="H001072" joined="2020-07-16"/>
    <cosponsor bioguide_id="S001187" joined="2020-07-16"/>
  </cosponsors>
  <actions>
    <action datetime="2020-07-16">
      <text>Introduced in House</text>
    </action>
    <action datetime="2020-07-16" state="REFERRED">
      <text>Referred to the House Committee on Financial Services.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSBA" name="House Financial Services" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="116" relation="identical" number="4218"/>
  </relatedbills>
  <subjects>
    <term name="Finance and financial sector"/>
    <term name="Accounting and auditing"/>
    <term name="Business investment and capital"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Corporate finance and management"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Government information and archives"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Securities"/>
    <term name="Small business"/>
    <term name="Wages and earnings"/>
  </subjects>
  <amendments/>
  <summary date="2020-07-16T04:00:00Z" status="Introduced in House">Coronavirus EGC Extension Act 

This bill extends the status of an issuer of securities as an emerging growth company. Specifically, these issuers will remain emerging growth companies until the later of

 one year after the date of enactment of this bill, the end of the COVID-19 (i.e., coronavirus disease 2019) emergency declaration period, and the date the issuer would otherwise cease being an emerging growth company. Emerging growth companies (in general, a newly public company with revenues below a specified threshold) are subject to reduced disclosure requirements, among other regulations.</summary>
  <committee-reports/>
</bill>
